混合基因型 HCV 直接作用抗病毒药物的疗效：CANUHC 分析。

IF 2.5 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Journal of Viral Hepatitis Pub Date : 2024-08-12 DOI:10.1111/jvh.13995

Haris Imsirovic, Gisela Macphail, Brian Conway, Chris Fraser, Sergio Borgia, Daniel Smyth, Alexander Wong, Marie-Louise Vachon, Duncan Webster, Hongqun Liu, Jordan Feld, Sam Lee, Curtis Cooper, the Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort Investigator Team

{"title":"混合基因型 HCV 直接作用抗病毒药物的疗效：CANUHC 分析。","authors":"Haris Imsirovic, Gisela Macphail, Brian Conway, Chris Fraser, Sergio Borgia, Daniel Smyth, Alexander Wong, Marie-Louise Vachon, Duncan Webster, Hongqun Liu, Jordan Feld, Sam Lee, Curtis Cooper, the Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort Investigator Team","doi":"10.1111/jvh.13995","DOIUrl":null,"url":null,"abstract":"<p>The prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV-positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not differ based on mixed genotype status. Any historical disadvantage to achieving cure with HCV treatment in mixed genotype infection has been overcome by current DAA regimens.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"31 11","pages":"775-779"},"PeriodicalIF":2.5000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.13995","citationCount":"0","resultStr":"{\"title\":\"Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis\",\"authors\":\"Haris Imsirovic, Gisela Macphail, Brian Conway, Chris Fraser, Sergio Borgia, Daniel Smyth, Alexander Wong, Marie-Louise Vachon, Duncan Webster, Hongqun Liu, Jordan Feld, Sam Lee, Curtis Cooper, the Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort Investigator Team\",\"doi\":\"10.1111/jvh.13995\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV-positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not differ based on mixed genotype status. Any historical disadvantage to achieving cure with HCV treatment in mixed genotype infection has been overcome by current DAA regimens.</p>\",\"PeriodicalId\":17762,\"journal\":{\"name\":\"Journal of Viral Hepatitis\",\"volume\":\"31 11\",\"pages\":\"775-779\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.13995\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Viral Hepatitis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jvh.13995\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Viral Hepatitis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvh.13995","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本研究报告了具有代表性的加拿大丙型肝炎病毒（HCV）队列中混合型丙型肝炎病毒（HCV）基因型感染的发病率，并评估了直接作用抗病毒药物（DAA）治疗的病毒学应答。共招募了 3272 名 HCV 阳性参与者，其中 2945 人（90.0%）开始接受 DAA 治疗。0.8%的患者被确认为混合基因型感染。总体持续病毒学应答（SVR）率为 99.1%，并不因混合基因型状态而有所不同。目前的 DAA 治疗方案已经克服了混合基因型感染患者在接受 HCV 治疗以获得治愈方面的任何历史性劣势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis

The prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV-positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not differ based on mixed genotype status. Any historical disadvantage to achieving cure with HCV treatment in mixed genotype infection has been overcome by current DAA regimens.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Viral Hepatitis 医学-病毒学

CiteScore

6.00

自引率

8.00%

发文量

138

审稿时长

1.5 months

期刊介绍： The Journal of Viral Hepatitis publishes reviews, original work (full papers) and short, rapid communications in the area of viral hepatitis. It solicits these articles from epidemiologists, clinicians, pathologists, virologists and specialists in transfusion medicine working in the field, thereby bringing together in a single journal the important issues in this expanding speciality. The Journal of Viral Hepatitis is a monthly journal, publishing reviews, original work (full papers) and short rapid communications in the area of viral hepatitis. It brings together in a single journal important issues in this rapidly expanding speciality including articles from: virologists; epidemiologists; clinicians; pathologists; specialists in transfusion medicine.